Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
We know that connecting with colleagues is essential. Meet new colleagues and catch up with everyone in your professional circle. Join us for the 2024…
This meta-analysis examines demographic and tumor characteristics and treatment approaches for different extramammary Paget disease subtypes and presents recommendations for diagnosis and treatment.
By Emily Margosian, Assistant Editor, April 1, 2024 Design a webpage. Make a content strategy. Answer medical questions. Write an essay about trickle-down economics in…
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
This Viewpoint discusses the need for a broader approach to nail pathology, in which infectious, inflammatory, systemic, and structural factors are considered.
This nonrandomized controlled trial analyzes the efficacy and safety of erenumab, an anti–calcitonin gene-related peptide receptor monoclonal antibody, for rosacea-associated erythema and flushing.
Thank you for your interest in the 25th Annual Las Vegas Dermatology Seminar in Las Vegas! MedscapeLIVE! is pleased to announce the 2024 seminar, with…
How much do you know about gastroesophageal reflux disease (GERD) and its diagnosis and treatment? In this engaging, interactive symposium, participants will get to test…
Create a non-member account if you are applying for membershi p or need to interact with AAD systems. Non-member accounts do not have access to…
A recent survey covered topics including skin-aging prevention, care-seeking behavior, trust in professionals, and more.